The US investment fund Warburg Pincus has annouced intentions to buy a majority stake in the Slovak drugs maker Slovakofarma through the target’s 61% majority shareholder SL Pharma, thus avoiding the need for a public offer.
Compiled by Tom Nicholson from press reports.
The Slovak Spectator cannot vouch for the accuracy of the information presented in its Flash News postings.
7. Dec 2001 at 8:41